<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Brakke Consulting&#x306E;&#x30A6;&#x30A7;&#x30D6;&#x30B5;&#x30A4;&#x30C8;</provider_name><provider_url>https://brakkeconsulting.com/ja</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="LQZtOvOSer"&gt;&lt;a href="https://brakkeconsulting.com/ja/23583/"&gt;2000 &#x5E74; 10 &#x6708; 27 &#x65E5;&#x306E;&#x52D5;&#x7269;&#x5065;&#x5EB7;&#x30CB;&#x30E5;&#x30FC;&#x30B9;&#x3068;&#x30CE;&#x30FC;&#x30C8;&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/ja/23583/embed/#?secret=LQZtOvOSer" width="600" height="338" title="&#x201C;&#x300C;2000&#x5E74;10&#x6708;27&#x65E5;&#x306E;&#x52D5;&#x7269;&#x885B;&#x751F;&#x30CB;&#x30E5;&#x30FC;&#x30B9;&#x3068;&#x30CE;&#x30FC;&#x30C8;&#x300D;&#x2014; Brakke Consulting&#x30A6;&#x30A7;&#x30D6;&#x30B5;&#x30A4;&#x30C8;" data-secret="LQZtOvOSer" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>**************************************************************** Brakke Consulting&rsquo;s Animal Health News &amp; Notes for October 27, 2000 Copyright &copy; Brakke Consulting, Inc. **************************************************************** Company Earnings Releases &gt;&nbsp; Pfizer reported that third quarter sales of Animal Health were $208 million, down 38% from the comparable period in 1999.&nbsp; The decline in sales reflected the size of the initial distribution of Revolution requested by veterinarians in the U.S. in the third quarter of 1999, competitive pressures on key brands, continuing weakness in U.S. and European livestock markets, and the negative impact of foreign exchange.&nbsp; On October 2, 2000, Pfizer announced that it was selling its medicinal feed additives business to Phibro Animal Health. (PRNewswire, company news) &gt;&nbsp; Novartis reported that nine month 2000 sales in its Animal Health division were CHF 789 million ($455 million), an increase of 5% over the comparable period in 1999.&nbsp; The positive trend in the Farm Animal business continued, led by the anti-infective tiamulin, which posted high double-digit growth. As expected, the companion animal business had to contend with strong competition in the flea and heartworm treatment segment, constraining sales of Sentinel (combined flea, intestinal and heartworm treatment for dogs), Program (flea prevention) and Interceptor (heartworm treatment).&nbsp; As expected, sales development remained sluggish in the US and reflected the earlier start to the fall sales campaign in 1999. The trend was positiveView Full Post;</description></oembed>
